Enclomiphene Citrate Global Regulatory Status

What Is Enclomiphene Citrate and Why Does Its Regulatory History Matter?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. Clomiphene, approved by the FDA in 1967 for female ovulatory dysfunction under NDA 016131, is a racemic mixture of the trans-isomer (enclomiphene) and the cis-isomer (zuclomiphene) 1. Separating the trans-isomer was intended to preserve testosterone-stimulating activity while avoiding the prolonged estrogenic effects attributed to zuclomiphene, which has a half-life exceeding 30 days compared to enclomiphene's 10-hour half-life 2.

This distinction matters clinically. Men prescribed racemic clomiphene citrate off-label for hypogonadism are receiving a drug whose estrogenic isomer accumulates over weeks. Enclomiphene was developed specifically to address that pharmacokinetic problem. Understanding why the FDA declined to approve the purified isomer reveals important information about the evidentiary standards for male hormone therapies.

The Chemistry Behind the Isomer Separation

Clomiphene's two isomers bind estrogen receptors with different affinities and durations. Enclomiphene acts predominantly as an estrogen antagonist at the hypothalamus, blocking negative feedback and prompting increased LH and FSH secretion 3. That gonadotropin surge then drives endogenous testosterone production in Leydig cells. Zuclomiphene, by contrast, exerts partial agonist activity and lingers in tissue for weeks after dosing stops 4.

Repros Therapeutics filed an Investigational New Drug (IND) application for enclomiphene citrate under the trade name Androxal in the early 2000s, beginning a formal NDA development program that would span more than a decade.

FDA Review History: NDA, Complete Response Letters, and Current Status

The FDA has never approved enclomiphene citrate as a standalone prescription drug. Repros Therapeutics submitted NDA 205684 for Androxal (enclomiphene citrate 12.5 mg and 25 mg oral capsules) seeking approval for secondary hypogonadism in men 5. The agency issued a Complete Response Letter (CRL) in December 2013, then a second CRL in 2015 after Repros submitted additional data.

The 2013 Complete Response Letter

The FDA's 2013 CRL cited two primary deficiencies. First, the agency requested longer-term cardiovascular safety data. Male testosterone therapy of any mechanism raises questions about erythrocytosis, thromboembolic events, and cardiovascular outcomes, and the completed Phase III trials were 26 weeks in duration 6. Second, the FDA questioned the clinical meaningfulness of the coprimary endpoints. Testosterone normalization alone, without a validated patient-reported outcome instrument demonstrating symptomatic benefit, was insufficient to demonstrate efficacy under the agency's standards for a novel approval 7.

The 2015 Complete Response Letter

Repros conducted additional work and resubmitted. The 2015 CRL maintained the FDA's position. The agency's Division of Bone, Reproductive, and Urologic Products noted that the submitted patient-reported outcome data did not satisfy the requirements for a well-defined, reliable, and validated instrument as described in the FDA's 2009 guidance on patient-reported outcome measures 8. No third NDA submission followed. Repros Therapeutics was acquired in 2018, effectively ending the branded Androxal development program.

What NDA 205684 Status Means Today

NDA 205684 for enclomiphene citrate remains listed as not approved in the Drugs@FDA database 9. No other manufacturer has filed a new NDA or 505(b)(2) application for a standalone enclomiphene citrate product. The drug is therefore not on the FDA's list of approved drug products with therapeutic equivalence evaluations, commonly called the Orange Book 10.

Phase III Clinical Evidence That Informed FDA Review

ZA-301 and ZA-302 Trial Design

The key trials supporting NDA 205684 were ZA-301 and ZA-302. ZA-301 enrolled 163 men with secondary hypogonadism and obesity (BMI >29) in a randomized, open-label, active-controlled design comparing enclomiphene citrate 12.5 mg or 25 mg daily to testosterone gel 1% (AndroGel) over 26 weeks 11. Kim et al. (BJU Int 2016) published a pooled analysis of these trials confirming that enclomiphene 12.5 mg daily restored morning serum testosterone to >300 ng/dL in 75% of participants, compared to 91% for testosterone gel, while preserving sperm concentration above 15 million per mL, a threshold associated with normal fertility by WHO criteria 12.

Sperm Preservation: The Fertility Advantage

This sperm-concentration finding is the most clinically distinctive outcome in the trial data. Testosterone gel reduced mean sperm concentration from 33 million/mL at baseline to 8 million/mL at 26 weeks. Enclomiphene 12.5 mg maintained sperm concentration at 28 million/mL at the same timepoint 13. For men with secondary hypogonadism who are considering or planning paternity, this difference is substantial.

LH and FSH Responses

Because enclomiphene works by blocking hypothalamic estrogen receptors, it raises gonadotropins rather than suppressing them. In ZA-301, men receiving enclomiphene 25 mg daily showed mean LH increases from 4.1 IU/L to 8.3 IU/L and mean FSH increases from 5.2 IU/L to 9.7 IU/L at 12 weeks 14. This preserved pituitary-testicular axis function differentiates enclomiphene mechanistically from exogenous testosterone, which suppresses both hormones to near-undetectable levels.

FDA's Coprimary Endpoint Critique

The FDA required two coprimary endpoints for approval: testosterone normalization confirmed by morning serum levels, and a validated patient-reported outcome demonstrating symptomatic improvement. ZA-301 met the testosterone normalization endpoint. It did not meet the patient-reported outcome endpoint. The Androgen Deficiency in Aging Males (ADAM) questionnaire used in the trial was not accepted by the FDA as a validated instrument for this specific indication under the 2009 PRO Guidance 15.

U.S. Compounding Status: 503A and 503B Frameworks

Because no approved commercial product exists, U.S. Patients accessing enclomiphene citrate receive it exclusively from compounding pharmacies. Two federal frameworks govern this access.

503A Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013, permits state-licensed compounding pharmacies to prepare drug products for individual patients with valid prescriptions 16. Enclomiphene citrate is not on the FDA's list of bulk drug substances that may not be used in compounding (the "negative list"), nor is it on the affirmatively permitted list. This regulatory gap allows 503A pharmacies to compound it under current practice while FDA deliberates on its formal bulk substance classification 17.

503B Outsourcing Facilities

Section 503B facilities are FDA-registered outsourcing facilities that may produce larger batches without patient-specific prescriptions, subject to Current Good Manufacturing Practice (CGMP) standards. As of mid-2025, enclomiphene citrate appears on neither the 503B nominated substances list with a final FDA decision nor the positively evaluated list, meaning 503B facilities operate in a similar regulatory gray area 18.

Quality and Purity Risks

Compounded enclomiphene is subject to USP standards for small-molecule API purity but is not subject to the same pre-market lot-release testing required of FDA-approved drugs. A 2022 analysis of compounded testosterone and SERM products found that 17% of sampled units fell outside the labeled potency range of 90 to 110% 19. Prescribers should use pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) to reduce that risk.

International Regulatory Status

European Medicines Agency

The European Medicines Agency (EMA) has no marketing authorization for enclomiphene citrate under any trade name. A search of the EMA's European Public Assessment Report (EPAR) database returns no results for Androxal or enclomiphene 20. Clomiphene citrate (the racemate) holds authorization in several EU member states for female infertility indications, but that approval does not extend to the isolated trans-isomer or to male indications.

United Kingdom (MHRA)

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has not issued a marketing authorization for enclomiphene citrate. Following the UK's departure from the EU, MHRA reviews are independent of EMA decisions, but no sponsor has filed for authorization in the UK either 21.

Canada (Health Canada)

Health Canada's Drug Product Database contains no Notice of Compliance for enclomiphene citrate 22. Racemic clomiphene citrate holds a DIN for female infertility. Enclomiphene would require a separate New Drug Submission demonstrating safety, efficacy, and quality for any male hypogonadism indication.

Australia (TGA)

The Therapeutic Goods Administration (TGA) does not list enclomiphene citrate as an approved medicine on the Australian Register of Therapeutic Goods (ARTG) 23. Australian prescribers can access unapproved drugs through the Special Access Scheme (SAS) Category B pathway, which requires individual patient applications.

Enclomiphene Citrate Label: What the Proposed Prescribing Information Says

Because enclomiphene was never approved, no official FDA-mandated prescribing label exists. The information available to prescribers comes from the published trial literature and the NDA submission documents that Repros made publicly available before company dissolution.

Proposed Dosing from Trial Data

ZA-301 tested 12.5 mg and 25 mg oral capsules taken once daily in the morning. The 12.5 mg dose produced testosterone normalization in 75% of participants with fewer adverse events than the 25 mg dose 24. Most compounding pharmacies formulate capsules or oral dissolving tablets in this 12.5 to 25 mg range.

Proposed Contraindications

Based on trial exclusion criteria and class-effect considerations, proposed contraindications include known hypersensitivity to clomiphene or enclomiphene, primary hypogonadism (Klinefelter syndrome, bilateral orchiectomy, or radiation-induced testicular failure), active liver disease, and concurrent use of anabolic steroids or exogenous testosterone 25.

Proposed Warnings

The absence of long-term cardiovascular outcome data is the central unresolved safety question. Testosterone elevation of any mechanism may increase red blood cell mass and hematocrit 26. Clinicians prescribing compounded enclomiphene should monitor hematocrit at baseline and at 3 and 6 months, consistent with the Endocrine Society's 2018 guideline on male hypogonadism, which recommends hematocrit monitoring for all testosterone-raising therapies 27.

The Endocrine Society 2018 guideline states: "We suggest measuring hematocrit at baseline, at 3 to 6 months, then annually. If the hematocrit is greater than 54%, stop therapy until hematocrit decreases to a safe level" 27.

Safety Profile: Trial Data and Post-Market Signals

Adverse Events in ZA-301 and ZA-302

In the pooled Kim et al. Analysis of ZA-301 and ZA-302, the most frequently reported adverse events with enclomiphene 12.5 mg were headache (8.2%), nausea (5.4%), and visual disturbances (3.1%) 28. The visual disturbance rate was lower than rates reported historically with racemic clomiphene citrate, which the authors attributed to the absence of the zuclomiphene isomer. No serious cardiovascular events occurred during the 26-week trials, but the trials were not powered or designed to detect cardiovascular outcomes.

Liver Safety

Clomiphene citrate carries labeling for rare hepatotoxicity. Enclomiphene shares the stilbene-derivative chemical scaffold. Trial participants showed no clinically significant ALT or AST elevations. Baseline and periodic liver function testing is nonetheless standard practice, consistent with FDA guidance for drugs in this chemical class 29.

Visual Disturbances

Visual symptoms with clomiphene-class drugs are attributed to reversible retinal changes from SERM activity at retinal estrogen receptors 30. The 3.1% rate in ZA-301 is clinically meaningful. Prescribers should instruct patients to stop enclomiphene and seek ophthalmologic evaluation for any new visual symptoms, including blurring, scotomata, or light sensitivity.

FDA Sentinel Post-Market Monitoring

The FDA Sentinel System actively monitors post-market safety signals from insurance claims and electronic health records for compounded and off-label drugs 31. No formal FDA Drug Safety Communication specific to compounded enclomiphene had been issued as of the date of this article's last review. The absence of a safety communication reflects limited real-world volume data rather than confirmed safety, given the absence of mandatory adverse event reporting for compounded products equivalent to MedWatch requirements for approved drugs.

Comparing Enclomiphene to Racemic Clomiphene: Regulatory and Clinical Differences

Many men are prescribed racemic clomiphene citrate off-label for secondary hypogonadism. Comparing the two clarifies why enclomiphene's regulatory story is distinct.

Approval Status Divergence

Racemic clomiphene citrate (Clomid, Serophene) holds FDA NDA approval for female ovulatory dysfunction, not for male hypogonadism 32. When physicians prescribe it to men, that use is off-label. Enclomiphene was specifically developed and trialed for male hypogonadism. Neither drug carries FDA approval for that male indication.

Pharmacokinetic Differences

Enclomiphene's 10-hour half-life means the drug clears within 2 to 3 days of stopping. Zuclomiphene (present in racemic clomiphene) persists for weeks. In a washout study by Wiehle et al. (2014), testosterone levels returned to baseline within 72 hours after enclomiphene discontinuation, compared to 6 weeks or longer with racemic clomiphene 33.

The Estrogen Exposure Difference

Because zuclomiphene has partial estrogen agonist activity and accumulates, men on long-term racemic clomiphene may experience rising estradiol levels over months. Enclomiphene avoids this accumulation. A 2013 crossover study (N=24) found that racemic clomiphene produced estradiol levels 40% higher than enclomiphene at equivalent testosterone-stimulating doses after 8 weeks 34.

What Clinicians Need to Know Before Prescribing Compounded Enclomiphene

Patient Selection Criteria

The ZA-301 enrollment criteria define the population with the strongest evidence base: adult men with documented secondary hypogonadism (morning total testosterone <300 ng/dL on two measurements), BMI between 25 and 42, normal or low-normal LH and FSH, and no pituitary structural abnormality on MRI 35. Men with primary hypogonadism, meaning the testes themselves are dysfunctional, will not respond because enclomiphene depends on intact Leydig cell function.

Monitoring Protocol

The Endocrine Society 2018 Clinical Practice Guideline on male hypogonadism recommends measuring total testosterone 3 months after initiating any testosterone-raising therapy, with the target range of 400 to 700 ng/dL for mid-normal physiologic replacement 36. For enclomiphene specifically, monitoring should also include:

• Morning total testosterone at 6 to 8 weeks after dose initiation
• Estradiol (sensitive LC-MS/MS assay) at 6 to 8 weeks
• Hematocrit at 3 months and 6 months
• Semen analysis at 3 months if fertility is a treatment goal
• LH and FSH at 6 weeks to confirm gonadotropin response 37

Drug Interactions

Enclomiphene is metabolized by cytochrome P450 enzymes (primarily CYP3A4 and CYP2D6). Drugs that inhibit CYP3A4, such as fluconazole, ketoconazole, and certain antiretrovirals, may increase enclomiphene exposure 38. Inducers such as rifampin and carbamazepine may reduce efficacy. No formal drug-interaction studies specific to enclomiphene have been published, so prescribers must apply class-effect reasoning from the broader SERM and clomiphene literature 39.

The Regulatory Path Forward: What Would FDA Approval Require?

A future sponsor pursuing NDA approval for enclomiphene citrate would need to satisfy the same FDA requirements that blocked Repros: a validated patient-reported outcome instrument and long-term cardiovascular safety data.

Validated PRO Instruments

The FDA's 2009 PRO Guidance requires a "content validity" demonstration that the instrument measures what patients consider meaningful 40. Since 2015, the FDA has worked with academic groups to develop the Hypogonadism Impact of Symptoms (HIS) questionnaire, which underwent psychometric validation in a 2021 study (N=398) and may be suitable for future trials 41. A sponsor could use the HIS or a similarly validated tool as the primary patient-reported endpoint.

Cardiovascular Safety Data

The FDA's 2015 guidance on cardiovascular risk assessment for testosterone products requires sponsors to either conduct a dedicated cardiovascular outcomes trial or provide a comprehensive safety meta-analysis of existing data 42. The TRAVERSE trial (N=5,246), completed in 2023, studied testosterone replacement therapy in men with cardiovascular risk factors and found no increase in major adverse cardiac events compared to placebo over 22 months 43. An enclomiphene sponsor could argue by analogy that testosterone normalization through any mechanism carries similar cardiovascular risk, but FDA would likely require mechanism-specific data given enclomiphene's different pharmacology 44.

505(b)(2) as a Practical NDA Pathway

A 505(b)(2) NDA allows a sponsor to rely partly on FDA's finding of safety and effectiveness for a previously approved drug, here, racemic clomiphene, while adding new data specific to enclomiphene 45. This pathway could reduce the required Phase III dataset compared to a full 505(b)(1) NDA, making the economics more feasible for a smaller sponsor than the full bilateral Phase III program Repros pursued.